Rilpivirine

SKU: orb1305674

Description

Rilpivirine (R278474) is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) active against HIV-1. It is utilized in antiretroviral therapy and is a key compound for in vitro virology research and in vivo studies investigating HIV treatment and drug resistance mechanisms.

Research Area

Infectious Disease & Virology, Pharmacology & Drug Discovery, Protein Biochemistry

Key Properties

• CAS Number: 500287-72-9
• MW: 366.42
• Purity: 98.83% (May vary between batches)
• Formula: C₂₂H₁₈N₆
• SMILES: N(C1=C(C)C=C(/C=C/C#N)C=C1C)C2=NC(NC3=CC=C(C#N)C=C3)=NC=C2
• Target: HIV Protease,Reverse Transcriptase
• Solubility: H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2.5 mg/mL (6.82 mM);DMSO:55 mg/mL (150.1 mM)

Bioactivity

• In Vivo:
  Rilpivirine demonstrates antiviral activity against both wild-type and selective point single and double HIV-1 mutants, with an effective concentration (EC50) ranging from 0.1 to 2 nM.
  Read more...
• In Vitro:
  Rilpivirine, dissolved in PEG 400 and administered via intravenous injection at dosages of 4 mg/kg in rats and 1.25 mg/kg in dogs, exhibits half-lives of 4.4 hours and 31 hours, respectively.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

transcriptase, Rilpivirine, ReverseTranscriptase, Reverse Transcriptase, reverse, resistance, R 278474, R278474, R-278474, TMC278, TMC-278, TMC 278, wild-type, HIV, HIV Protease, HIVProtease, Human immunodeficiency virus, Inhibitor, inhibit, non-nucleoside, mutant, NNRTI, DAPY, DB 08864, DB08864, DB-08864, diarylpyrimidine, antiviral

Compound Identifiers

PubChem CID

6451164